ClinicalTrials.gg
CompletedNCT01787552Updated Apr 15, 2020Results posted

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

A Phase 1/2 interventional study of LDE225 and INC424 in Primary Myelofibrosis, Thrombocytosis and Essential Thrombocythemia, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Primary Myelofibrosis by Novartis — 1 open to participants now, 4 under way, 2 of them phase 3. Primary Myelofibrosis · Novartis.

Enrollment
13th of 21
50 · median 51
Started
2013
the only one that year
Phase 1/2
2 of 24
none open now
Registered
10th of 24
by date

Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1/2, and was the 10th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

1 of the 24 studies in Primary Myelofibrosis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Primary Myelofibrosis by Novartis, or all of them as a file.
02

Study summary

The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the combination and b) to assess the efficacy of the co-administration of LDE225 and INC424 on spleen volume reduction.

Read the detailed description

The study is considered to have been completed because the participants completed the study as per study design at the time of trial termination. If participants were already in extension phase until discontinuation criteria were met or alternative setting was available, they were considered as completed. The study was terminated due to one of the compounds being divested.

03

Conditions studied

  • Primary Myelofibrosis
  • Thrombocytosis
  • Essential Thrombocythemia
  • Polycythemia Vera
  • Myeloproliferative Disorders
  • Bone Marrow Diseases
  • Hematologic Diseases
  • Blood Coagulation Disorders
  • Blood Platelet Disorders
  • Hemorrhagic Disorders

Keywords

  • Dose escalation
  • Maximum Tolerated Dose
  • MTD
  • Safety Expansion
  • Safety
  • Efficacy
  • Myelofibrosis
  • Post-polycythemia vera myelofbrosis (Post PV-PMF)
  • Post essential thrombocythemia myelofibrosis (Post ET-MF)
  • Primary myelofibrosis (PMF)
  • Intermediate risk myelofibrosis
  • High risk myelofibrosis
  • Combination Treatment
  • Hedgehog Signaling Pathway
  • Smoothened inhibitor
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with PMF per 2008 WHO criteria, post-PV MF or post-ET MF per IWG-MRT criteria.
  • Ineligible or unwilling to undergo stem cell transplantion.
  • counts > or = 75X 10\^9/L not reached with the aid of transfusions.
  • performance status ≤ 2.
  • Palpable splenomegaly defined as ≥ 5 cm below the left costal margin.
  • Intermediate risk level 1 (1 prognostic factor which is not age), Intermediate risk level 2, or high risk.
  • Active symptoms of MF as demonstrated by one symptom score of at least 5 (0 to10 point scale) or two symptom scores of at least 3 (0 to 10 point scale) on the MF Symptom Assessment Form (MFSAF).

Exclusion criteria

Exclusion Criteria:

  • Previous therapy with JAK or Smoothened inhibitors.
  • Patient is currently on medications that interfere with coagulation (including warfarin) or function with the exception of low dose aspirin (up to 100 mg) and LMWH.
  • Impairment of GI function or GI disease that may significantly alter the absorption of INC424 or LDE225 (e.g., uncontrolled nausea, vomiting, diarrhea; malabsorption syndrome; small bowel resection).
  • Splenic irradiation within 12 months prior to Screening.
  • Pregnant or nursing women.
  • not using highly effective methods of
  • Sexually active males who refuse condom use
  • Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as HMG CoA inhibitors (statins), clofibrate and gemfibrozil. Pravastatin may be used if necessary, with extra caution.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    LDE225 + INC424

    LDE225 and INC424 in combination

    Drug: LDE225 · Drug: INC424

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b)

    A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.

    Time frame: 6 weeks (42 days)

  2. Percentage of Patients Achieving >= 35% Reduction in Spleen Volume in Phase Ib Expansion and Phase II Stage 1

    Reduction in spleen volume as measured by magnetic resonance imaging/Cat Scan (MRI/CT) in Phase Ib expansion and Phase II Stage 1 patients

    Time frame: Week 24 and Week 48

Secondary outcomes

  1. Phase Ib and Phase II: LDE225: Plasma Pharmacokinetics (PK) Parameter: Area Under the Curve(AUC0-24h)

    Plasma Concentration Time Curve: AUC0-24h: Area under the concentration-time curve from time zero to 24 hours extrapolate from AUClast\[mass x time x volume-1\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1

  2. Phase Ib and Phase II: INC424: PK Parameters: Area Under the Curve for AUC0-12h, AUCinf & AUClast

    AUC0-12h: Area under the concentration-time curve from time zero to 12 hours extrapolate from AUClast\[mass x time x volume-1\]. AUCinf: Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase \[mass x time x volume-1\]. AUClast: Area under the concentration-time curve from time zero to the time of last measurable concentration \[mass x time x volume-1\].

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1

  3. Phase Ib and Phase II: LDE225 & INC424: PK Parameter: Maximum Plasma Concentration (Cmax)

    Cmax: Maximum observed plasma concentration after drug administration \[mass x volume- 1\].

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1

  4. Phase Ib and Phase II: LDE225 & INC424: Plasma PK Parameter: Time to Maximum Plasma Concentration (Tmax)

    Tmax: Time to reach Cmax \[time\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1

  5. Phase Ib and Phase II: LDE225 & INC424:: Plasma Pharmacokinetics (PK) Parameters: Area Under the Curve(CL/F)

    CL/F: Apparent total plasma clearance of drug after oral administration \[volume x time-1\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1

  6. Phase Ib and Phase II: Percentage of Participants With Fibrosis Grade Assessed by Bone Marrow Histomorphology, by Time and Treatment in Phase Ib and Phase II Stage 1

    The number of patients experiencing improvement in their bone marrow fibrosis by at least one grade and assessment of cellularity.

    Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)

  7. Phase Ib and Phase ll: Summary of JAK2V617F Allele Burden by Visit and Treatment in Phase Ib and Phase II Stage 1

    Phase Ib and Phase ll: Change in Pharmacodynamic Biomarkers: JAK2V617F allele burden

    Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)

  8. Phase Ib and Phase ll: Summary of Cytokine Levels in Pharmacodynamic for All Collected Biomarkers

    Summary of cytokine levels in Pharmacodynamic Biomarkers for all 26 collected at Week 25 Day 1 and Week 49 Day 1

    Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)

  9. Phase Ib and Phase II: Percentage of Participants With >= 50% Reduction From Baseline in MFSAF Total Symptom Scores

    The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.

    Time frame: Week 24, Week 48

  10. Phase Ib and Phase II: Change in Total Symptom Score (TSS) From Baseline to Week 25 & Week 49 Using the MFSAF Total Symptom Scores

    The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.

    Time frame: Baseline, Week 25, Week 49

  11. Phase I and Phase II: Change in EORTC QLQ-C30 Scores From Baseline Compared to Week 24 & Week 48

    EORTC QLQ-C30 is the European Organization for Research \& Treatment of Cancer, Quality of Life (QoL) Questionnaire \& is one of the most widely used \& validated instruments to measure health-related QoL in subjects with cancer. The scale includes 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning \& social functioning), global health status/QoL \& 9 symptom scale/items (fatigue, nausea \& vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, \& financial difficulties). This instrument asks the subject to respond according to the past week, with the exception of the first 5 questions that represent physical functioning \& capture the subject's current status. The range of scores for all of the scales is from 0 to 100. For functional \& global health status/QoL scales, higher scores indicate better QoL \& level of functioning; for symptom scales, higher scores indicate greater level of symptoms or difficulties.

    Time frame: Week 24, Week 48

  12. Phase Ib and Phase II: LDE225: PK Parameter: Racc

    Racc: Accumulation ratio calculated as AUC0-12h on Week 9 Day 1 divided by AUC0-12h on Week 1 Day 1 \[fold\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 9 Day 1

  13. Phase Ib and Phase II: INC424: PK Parameter: T1/2

    T1/2: Elimination half-life associated with the terminal slope (lambda_z) of a semi logarithmic concentration-time curve \[time\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1

  14. Phase Ib and Phase II: INC424: PK Parameter: Vss/F

    Vss/F: Apparent volume of distribution at steady state after oral administration \[volume\]

    Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1

07

Results

Posted Apr 15, 2020
Limitations and caveats
Please refer to detailed description regarding reason for early termination of study.

Participant flow

A total of 50 subjects were enrolled in the study, of which 23 subjects were enrolled in Phase Ib part of dose-escalation phase and 27 subjects were enrolled in Phase Ib dose-expansion phase and Phase II Stage 1.

Participant flow — Overall Study
MilestoneLDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15 mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Started810527
Completed0100
Not completed89527
Withdrew: Withdrawal by subject2004
Withdrew: Physician decision2212
Withdrew: Death0001
Withdrew: Adverse event25216
Withdrew: Study terminated by sponsor0013
Withdrew: Progressive disease2211

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b)

A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.

Time frame:
6 weeks (42 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b)
ParticipantsLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Blood creatine phosphokinase increased0201
PrimaryPercentage of Patients Achieving >= 35% Reduction in Spleen Volume in Phase Ib Expansion and Phase II Stage 1

Reduction in spleen volume as measured by magnetic resonance imaging/Cat Scan (MRI/CT) in Phase Ib expansion and Phase II Stage 1 patients

Time frame:
Week 24 and Week 48
Reported as:
Number · Percentage of Participants
Percentage of Patients Achieving >= 35% Reduction in Spleen Volume in Phase Ib Expansion and Phase II Stage 1
Percentage of ParticipantsLDED225 400mg + INC424 20mg (Dose Expansion Phase)
Week 2444.4
Week 4829.6
SecondaryPhase Ib and Phase II: LDE225: Plasma Pharmacokinetics (PK) Parameter: Area Under the Curve(AUC0-24h)

Plasma Concentration Time Curve: AUC0-24h: Area under the concentration-time curve from time zero to 24 hours extrapolate from AUClast\[mass x time x volume-1\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Reported as:
Geometric mean · ng*hr/mL
Phase Ib and Phase II: LDE225: Plasma Pharmacokinetics (PK) Parameter: Area Under the Curve(AUC0-24h)
ng*hr/mLLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
LDE225 (Week 1, Day 1) (n=6,10,4,24)2680 ± 33.11900 ± 100.41090 ± 84.02060 ± 78.7
LDE225 (Week 9, Day 1) (n=6,6,4,14)15500 ± 31.813000 ± 66.817100 ± 30.814500 ± 45.4
SecondaryPhase Ib and Phase II: INC424: PK Parameters: Area Under the Curve for AUC0-12h, AUCinf & AUClast

AUC0-12h: Area under the concentration-time curve from time zero to 12 hours extrapolate from AUClast\[mass x time x volume-1\]. AUCinf: Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase \[mass x time x volume-1\]. AUClast: Area under the concentration-time curve from time zero to the time of last measurable concentration \[mass x time x volume-1\].

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Reported as:
Geometric mean · ng*hr/mL
Phase Ib and Phase II: INC424: PK Parameters: Area Under the Curve for AUC0-12h, AUCinf & AUClast
ng*hr/mLLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
AUC0-12h: Wk1 Day 1 (n=8,10,5,25)473 ± 29.5805 ± 45.61130 ± 23.01190 ± 41.0
AUC0-12h: Wk 9 Day 1 (n=8,9,4,20)489 ± 42.5835 ± 46.6962 ± 23.71230 ± 42.4
AUCinf: Wk1 Day 1 (n=7,9,4,16)466 ± 30.9789 ± 46.11140 ± 28.01130 ± 47.7
AUCinf: Wk 9 Day 1 (n=8,9,3,15)498 ± 43.1867 ± 48.7978 ± 29.51140 ± 43.0
AUClast: Wk1 Day 1 (n=8,10,5,26)443 ± 26.2730 ± 39.71030 ± 20.81070 ± 38.6
AUClast: Wk 9 Day 1 (n=8,9,4,20)460 ± 44.3776 ± 43.9891 ± 24.31130 ± 38.6
SecondaryPhase Ib and Phase II: LDE225 & INC424: PK Parameter: Maximum Plasma Concentration (Cmax)

Cmax: Maximum observed plasma concentration after drug administration \[mass x volume- 1\].

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Reported as:
Geometric mean · ng/mL
Phase Ib and Phase II: LDE225 & INC424: PK Parameter: Maximum Plasma Concentration (Cmax)
ng/mLLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
LDE225 (Week 1, Day 1) (n=6,10,5,26)311 ± 35.1221 ± 103.4161 ± 94.9251 ± 83.4
LDE225 (Week 9, Day 1) (n=8,8,5,20)879 ± 38.0720 ± 57.5959 ± 39.4951 ± 51.1
INC424 (Week 1, Day 1) (n=8,10,5,27)154 ± 29.0244 ± 40.4351 ± 27.7338 ± 40.1
INC424 (Week 9, Day 1) (n=8,9,4,20)168 ± 38.8269 ± 33.2281 ± 36.5350 ± 36.0
SecondaryPhase Ib and Phase II: LDE225 & INC424: Plasma PK Parameter: Time to Maximum Plasma Concentration (Tmax)

Tmax: Time to reach Cmax \[time\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Reported as:
Median · hour (hr)
Phase Ib and Phase II: LDE225 & INC424: Plasma PK Parameter: Time to Maximum Plasma Concentration (Tmax)
hour (hr)LDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
LDE225 (Week 1, Day 1) (n=6,10,5,26)3.01 (2.00 to 4.00)2.08 (1.50 to 4.22)2.00 (1.50 to 8.00)2.00 (1.00 to 6.00)
LDE225 (Week 9, Day 1) (n=8,8,5,20)1.79 (0.170 to 4.00)2.00 (1.50 to 4.00)2.00 (1.50 to 6.00)3.21 (1.50 to 23.9)
INC424 (Week 1, Day 1) (n=8,10,5,27)0.500 (0.500 to 2.00)0.575 (0.330 to 2.03)0.500 (0.500 to 0.970)0.580 (0.420 to 4.00)
INC424 (Week 9, Day 1) (n=8,9,4,20)0.875 (0.170 to 1.50)0.500 (0.500 to 1.52)1.00 (0.500 to 1.00)1.00 (0.330 to 2.00)
SecondaryPhase Ib and Phase II: LDE225 & INC424:: Plasma Pharmacokinetics (PK) Parameters: Area Under the Curve(CL/F)

CL/F: Apparent total plasma clearance of drug after oral administration \[volume x time-1\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Reported as:
Median · L/hr
Phase Ib and Phase II: LDE225 & INC424:: Plasma Pharmacokinetics (PK) Parameters: Area Under the Curve(CL/F)
L/hrLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
LDE225 (Week 1, Day 1) (n=5,5,1,12)145 (120 to 166)238 (53.7 to 508)727 (727 to 727)122 (46.2 to 525)
LDE225 (Week 9, Day 1) (n=6,6,4,14)27.8 (14.9 to 35.7)34.5 (12.9 to 62.3)25.1 (15.4 to 30.9)27.0 (12.6 to 56.9)
INC424 (Week 1, Day 1) (n=7,9,4,16)23.8 (12.2 to 26.9)18.7 (9.04 to 39.0)16.5 (13.3 to 25.6)16.9 (7.54 to 35.0)
SecondaryPhase Ib and Phase II: Percentage of Participants With Fibrosis Grade Assessed by Bone Marrow Histomorphology, by Time and Treatment in Phase Ib and Phase II Stage 1

The number of patients experiencing improvement in their bone marrow fibrosis by at least one grade and assessment of cellularity.

Time frame:
Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Reported as:
Number · Percentage of Participants
Phase Ib and Phase II: Percentage of Participants With Fibrosis Grade Assessed by Bone Marrow Histomorphology, by Time and Treatment in Phase Ib and Phase II Stage 1
Percentage of ParticipantsLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Baseline, grade 0 (n=0,0,0,1)———3.7
Baseline, grade 1 (n=0,1,0,4)—10.0—14.8
Baseline, grade 2 (n=4,6,3,8)50.050.060.029.6
Baseline, grade 3 (n=3,3,0,8)37.530.0—29.6
Baseline, missing grade (n=1,0,2,6)12.5—40.022.2
Week 25 Day 1, grade 1 (n=1,1,0,1)12.510.0—3.7
Week 25 Day 1, grade 2 (n=0,3,2,7)—30.040.025.9
Week 25 Day 1, grade 3 (n=5,4,1,5)62.540.020.018.5
Week 25 Day 1, missing grade (n=2,2,2,14)25.020.040.051.9
Week 49 Day 1, grade 0 (n=0,0,0,1)———3.7
Week 49, Day 1 grade 1 (n=0,0,0,1)———3.7
Week 49 Day 1, grade 2 (n=0,1,1,2)—10.020.07.4
Week 49 Day 1, grade 3 (n=2,2,2,3)25.020.040.011.1
Week 49 Day 1, missing grade (n=6,7,2,20)75.070.040.074.1
SecondaryPhase Ib and Phase ll: Summary of JAK2V617F Allele Burden by Visit and Treatment in Phase Ib and Phase II Stage 1

Phase Ib and Phase ll: Change in Pharmacodynamic Biomarkers: JAK2V617F allele burden

Time frame:
Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Reported as:
Median · Percentage of JAK allele burden mutation
Phase Ib and Phase ll: Summary of JAK2V617F Allele Burden by Visit and Treatment in Phase Ib and Phase II Stage 1
Percentage of JAK allele burden mutationLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Baseline84.7 (48.4 to 95.1)61.7 (2.5 to 92.1)88.3 (52.7 to 94.4)55.4 (2.5 to 93.5)
Week 25 Day 1 (n=7,6,5,21)88.6 (49.8 to 94.1)48.0 (2.5 to 78.4)74.9 (52.1 to 89.6)43.8 (2.5 to 93.9)
Week 49 Day 1 (n=4,3,4,13)86.0 (20.1 to 94.1)54.3 (2.5 to 80.0)75.7 (56.9 to 90.0)46.1 (2.5 to 85.6)
SecondaryPhase Ib and Phase ll: Summary of Cytokine Levels in Pharmacodynamic for All Collected Biomarkers

Summary of cytokine levels in Pharmacodynamic Biomarkers for all 26 collected at Week 25 Day 1 and Week 49 Day 1

Time frame:
Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Reported as:
Median · ng/mL
Phase Ib and Phase ll: Summary of Cytokine Levels in Pharmacodynamic for All Collected Biomarkers
ng/mLLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
AFP: Week 25 Day 1 (Wk 25 D1) (n=7,8,5,22)0.75 (0.3 to 2.5)0.79 (0.3 to 1.4)1.10 (0.3 to 2.2)0.49 (0.49 to 2.0)
AFP: Week 49 Day 1 (WK25 D1) (n=4,3,4,14)0.68 (0.3 to 1.6)0.60 (0.5 to 0.9)0.49 (0.49 to 1.1)0.49 (0.49 to 2.6)
APOA-1: Week 25 Day 1 (n=7,8,5,22)1.10 (0.7 to 1.7)1.65 (1.0 to 2.2)1.60 (1.2 to 1.6)2.10 (1.5 to 3.8)
APOA-1: Week 49 Day 1 (n=4,3,4,14)1.30 (0.9 to 1.5)1.50 (1.0 to 2.9)1.80 (1.6 to 2.6)2.05 (1.4 to 3.1)
B2M: Week 25 Day 1 (n=7,8,5,22)5.00 (2.8 to 7.4)3.15 (2.1 to 5.9)3.70 (2.4 to 5.2)3.15 (1.8 to 7.2)
B2M: Week 49 Day 1 (n=4,3,4,14)5.75 (4.5 to 11.0)4.60 (1.9 to 6.1)3.25 (2.4 to 4.4)3.00 (1.0 to 6.3)
BDNF: Week 25 Day 1 (n=7,8,5,22)0.46 (0.0 to 2.0)0.85 (0.2 to 2.5)0.15 (0.1 to 0.4)0.55 (0.0 to 2.7)
BDNF: Week 49 Day 1 (n=4,3,4,14)1.16 (0.3 to 2.4)0.19 (0.0 to 3.8)0.41 (0.0 to 5.6)0.52 (0.0 to 12.0)
C Reactive Protein: Week 25 Day 1 (n=7,8,5,22)2.60 (1.0 to 16.0)2.70 (0.3 to 51.0)1.30 (0.1 to 4.1)4.50 (0.1 to 182.0)
C Reactive Protein: Week 49 Day 1 (n=4,3,4,14)4.65 (0.4 to 9.0)2.40 (0.0 to 6.3)1.30 (0.7 to 2.5)0.79 (0.1 to 30.0)
Carcinoembryyonic Antigen: Wk 25 D1 (n=7,8,5,22)1.40 (0.3 to 58.0)1.20 (0.8 to 5.6)1.20 (0.3 to 3.4)1.80 (0.2 to 12.0)
Carcinoembryyonic Antigen: Wk 49 D1 (n=4,3,4,14)1.72 (0.8 to 3.7)1.20 (1.1 to 1.3)1.45 (0.5 to 2.6)1.80 (0.5 to 12.0)
Cluster of. Diff 40: Wk 25 D1 (n=7,7,5,0)1.90 (0.8 to 3.4)1.10 (0.6 to 1.6)0.91 (0.6 to 1.4)—
Cluster of. Diff 40: Wk 49 D1 (n=4,2,0,0)1.65 (0.9 to 2.4)1.3 (1.2 to 1.4)——
Eotaxin1: Wk 25 D1 (n=7,8,5,22)155.00 (42.5 to 214.0)119.00 (42.5 to 429.0)101.00 (42.5 to 152.0)118.00 (58.5 to 294.0)
Eotaxin1: Wk 49 D1 (n=4,3,4,14)136.00 (42.5 to 290.0)145.00 (58.5 to 622.0)157.00 (58.5 to 380.0)175.00 (58.5 to 360.0)
ICAM1: Wk 25 D1 (n=7,8,5,22)266.00 (139.0 to 451.0)203.00 (137.0 to 339.0)168.00 (82.0 to 316.0)185.50 (93.0 to 324.0)
ICAM1: Wk 49 D1 (n=4,3,4,14)321.00 (95.0 to 470.0)173.00 (94.0 to 193.0)152.50 (91.0 to 553.0)163.00 (92.0 to 310.0)
IL10: Wk 25 D1 (n=7,8,5,22)9.30 (6.9 to 21.0)7.50 (3.4 to 11.0)3.40 (3.4 to 12.0)6.23 (4.1 to 29.0)
IL10: Wk 49 D1 (n=4,3,4,14)8.10 (3.4 to 12.0)4.05 (3.4 to 18.0)11.00 (8.4 to 24.0)8.40 (4.1 to 28.0)
IL18: Wk 25 D1 (n=7,8,5,22)292.00 (132.0 to 520.0)220.50 (108.0 to 907.0)445.00 (161.0 to 687.0)415.50 (127.0 to 1160.0)
IL18: Wk 49 D1 (n=4,3,4,14)278.00 (146.0 to 606.0)199.00 (168.0 to 575.0)550.50 (313.0 to 1260.0)318.50 (134.0 to 886.0)
IL1B: Wk 25 D1 (n=7,8,5,22)3.30 (3.3 to 3.3)3.30 (3.3 to 4.3)3.30 (3.3 to 6.9)4.3 (4.3 to 16.0)
IL1B: Wk 49 D1 (n=4,3,4,14)3.30 (3.3 to 3.3)3.30 (3.3 to 4.3)4.3 (4.3 to 8.9)4.3 (4.3 to 10.0)
IL1RN: Wk 25 D1 (n=7,8,5,22)130.00 (92.0 to 218.0)147.00 (85.0 to 496.0)114.00 (89.0 to 183.0)88.00 (63.0 to 328.0)
IL1RN: Wk 49 D1 (n=4,3,4,14)98.00 (71.0 to 124.0)281.00 (29.5 to 782.0)88.00 (73.0 to 214.0)85.50 (29.5 to 162.0)
IL6: Wk 25 D1 (n=7,8,5,22)4.70 (2.3 to 6.8)2.3 (2.3 to 6.3)2.3 (2.3 to 6.0)3.40 (3.4 to 11.0)
IL6: Wk 49 D1 (n=4,3,4,14)3.48 (2.3 to 6.8)3.40 (2.3 to 4.7)3.40 (3.4 to 11.0)3.40 (3.4 to 7.3)
IL8: Wk 25 D1 (n=7,8,5,22)28.00 (15.0 to 84.0)9.50 (7.2 to 74.0)15.00 (10.0 to 34.0)29.50 (6.9 to 280.0)
IL8: Wk 49 D1 (n=4,3,4,14)18.50 (9.6 to 161.0)11.00 (8.4 to 19.0)58.50 (19.0 to 166.0)32.00 (3.1 to 261.0)
Insulin: Wk 25 D1 (n=7,8,5,22)2.70 (0.8 to 5.4)1.35 (0.6 to 3.3)2.30 (1.8 to 3.8)0.6 (0.6 to 8.9)
Insulin: Wk 49 D1 (n=4,3,4,14)2.90 (1.4 to 3.1)2.90 (0.6 to 4.9)1.65 (0.6 to 3.0)1.60 (0.6 to 14.0)
LEP: Wk 25 D1 (n=7,8,5,22)1.50 (0.7 to 34.0)4.75 (1.2 to 30.0)6.00 (3.4 to 6.1)6.40 (1.2 to 49.0)
LEP: Wk 49 D1 (n=4,3,4,14)3.45 (0.7 to 16.0)17.00 (2.7 to 29.0)5.95 (1.0 to 10.0)5.60 (3.3 to 28.0)
Macro. Inflam. Prot-1 Beta: Wk 25 D1 (n=7,8,5,22)491.00 (269.0 to 1160.0)375.50 (203.0 to 1260.0)410.00 (330.0 to 873.0)513.00 (190.0 to 1010.0)
Macro. Inflam. Prot-1 Beta: Wk 49 D1 (n=4,3,4,14)406.50 (242.0 to 758.0)487.00 (357.0 to 594.0)970.50 (489.0 to 1850.0)521.00 (159.0 to 1100.0)
Macro.-derived Chemokine: Wk 25 D1 (n=7,8,5,22)253.00 (43.0 to 599.0)274.00 (93.0 to 1040.0)516.00 (193.0 to 1100.0)254.00 (55.0 to 760.0)
Macro.-derived Chemokine: Wk 49 D1 (n=4,3,4,14)190.50 (9.5 to 852.0)327.00 (218.0 to 963.0)430.50 (132.0 to 801.0)212.00 (97.0 to 696.0)
MPO: Wk 25 D1 (n=7,8,5,22)327.00 (127.0 to 1600.0)323.00 (134.0 to 3120.0)335.00 (134.0 to 3350.0)164.50 (63.0 to 1310.0)
MPO: Wk 49 D1 (n=4,3,4,14)175.00 (87.0 to 377.0)180.00 (122.0 to 1340.0)237.00 (147.0 to 794.0)116.50 (43.0 to 1760.0)
Myoglobin: Wk 25 D1 (n=7,8,5,22)31.00 (19.0 to 51.0)31.50 (16.0 to 47.0)54.00 (28.0 to 112.0)39.50 (16.0 to 140.0)
Myoglobin: Wk 49 D1 (n=4,3,4,14)35.00 (13.0 to 47.0)18.00 (14.0 to 49.0)45.50 (31.0 to 55.0)45.00 (14.0 to 76.0)
Plasmin. Activ. Inhibitor 1: Wk 25 D1 (n=7,8,5,22)34.00 (13.0 to 52.0)45.50 (9.2 to 73.0)17.00 (12.0 to 41.0)51.50 (5.5 to 240.0)
Plasmin. Activ. Inhibitor 1: Wk 49 D1 (n=4,3,4,14)31.50 (12.0 to 42.0)25.00 (13.0 to 80.0)49.00 (14.0 to 117.0)52.50 (21.0 to 226.0)
RANTES: Wk 25 D1 (n=7,8,5,22)4.80 (1.6 to 15.0)5.85 (1.6 to 18.0)4.20 (1.8 to 13.0)8.80 (0.3 to 37.0)
RANTES: Wk 49 D1 (n=4,3,4,14)8.25 (3.4 to 14.0)3.20 (0.7 to 14.0)10.55 (0.9 to 35.0)6.50 (0.8 to 73.0)
Thyroxine binding globulin Wk 25 D1 (n=7,8,5,22)38.00 (31.0 to 47.0)41.50 (30.0 to 75.0)45.00 (40.0 to 67.0)54.50 (33.0 to 82.0)
Thyroxine binding globulin: Wk 49 D1 (n=4,3,4,14)42.00 (29.0 to 58.0)45.00 (38.0 to 51.0)72.50 (71.0 to 76.0)54.00 (37.0 to 76.0)
TNFA: Wk 25 D1 (n=7,8,5,22)27.00 (7.0 to 77.0)18.50 (7.0 to 79.0)25.00 (16.0 to 38.0)12.00 (12.0 to 319.0)
TNFA: Wk 49 D1 (n=4,3,4,14)32.50 (7.0 to 57.0)32.00 (12.0 to 51.0)26.50 (12.0 to 112.0)12.00 (12.0 to 79.0)
TNFRT 2: Wk 25 D1 (n=7,8,5,22)33.00 (16.0 to 36.0)12.00 (6.2 to 53.0)15.00 (7.8 to 30.0)17.50 (5.9 to 40.0)
TNFRT 2: Wk 49 D1 (n=4,3,4,14)28.00 (21.0 to 38.0)21.00 (5.5 to 29.0)16.00 (12.0 to 27.0)12.50 (3.8 to 33.0)
VCAM1: Wk 25 D1 (n=7,8,5,22)2040.00 (1200.0 to 3420.0)1130.00 (809.0 to 2830.0)1690.00 (986.0 to 2770.0)1930.00 (984.0 to 3760.0)
VCAM1: Wk 49 D1 (n=4,3,4,14)2425.00 (1200.0 to 3220.0)1210.00 (1160.0 to 2230.0)2225.00 (1410.0 to 3050.0)1715.00 (1030.0 to 3260.0)
VEGF: Wk. 25 D1 (n=7,8,5,22)145.00 (132.0 to 429.0)202.50 (133.0 to 301.0)108.00 (64.0 to 113.0)168.00 (86.0 to 469.0)
VEGF: Wks. 49 D1 (n=4,3,4,14)227.00 (56.0 to 286.0)106.00 (83.0 to 223.0)163.00 (87.0 to 406.0)217.00 (87.0 to 543.0)
VWF: Wk. 25 D1 (n=7,8,5,22)135.00 (78.0 to 726.0)65.50 (34.0 to 140.0)398.00 (81.0 to 1540.0)156.50 (26.0 to 1230.0)
VWF: Wk. 49 D1 (n=4,3,4,14)140.50 (26.0 to 385.0)67.00 (37.0 to 110.0)716.00 (25.0 to 2200.0)154.50 (28.0 to 2290.0)
SecondaryPhase Ib and Phase II: Percentage of Participants With >= 50% Reduction From Baseline in MFSAF Total Symptom Scores

The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.

Time frame:
Week 24, Week 48
Reported as:
Number · Percentage of participants
Phase Ib and Phase II: Percentage of Participants With >= 50% Reduction From Baseline in MFSAF Total Symptom Scores
Percentage of participantsLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Week 2450.00 (15.70 to 84.30)40.0 (12.16 to 73.76)80.0 (28.36 to 99.49)33.3 (16.52 to 53.96)
Week 4825.00 (3.19 to 65.09)20.0 (2.52 to 55.61)80.0 (28.36 to 99.49)18.5 (6.30 to 38.08)
SecondaryPhase Ib and Phase II: Change in Total Symptom Score (TSS) From Baseline to Week 25 & Week 49 Using the MFSAF Total Symptom Scores

The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.

Time frame:
Baseline, Week 25, Week 49
Reported as:
Mean · scores on a scale
Phase Ib and Phase II: Change in Total Symptom Score (TSS) From Baseline to Week 25 & Week 49 Using the MFSAF Total Symptom Scores
scores on a scaleLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Week 25 (n = 6, 7, 5, 19)-18.8 ± 15.20-14.0 ± 8.58-19.4 ± 6.43-6.5 ± 9.26
Week 49 (n = 4, 5, 4, 10)-18.5 ± 12.07-13.6 ± 10.43-21.0 ± 5.66-8.0 ± 14.61
SecondaryPhase I and Phase II: Change in EORTC QLQ-C30 Scores From Baseline Compared to Week 24 & Week 48

EORTC QLQ-C30 is the European Organization for Research \& Treatment of Cancer, Quality of Life (QoL) Questionnaire \& is one of the most widely used \& validated instruments to measure health-related QoL in subjects with cancer. The scale includes 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning \& social functioning), global health status/QoL \& 9 symptom scale/items (fatigue, nausea \& vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, \& financial difficulties). This instrument asks the subject to respond according to the past week, with the exception of the first 5 questions that represent physical functioning \& capture the subject's current status. The range of scores for all of the scales is from 0 to 100. For functional \& global health status/QoL scales, higher scores indicate better QoL \& level of functioning; for symptom scales, higher scores indicate greater level of symptoms or difficulties.

Time frame:
Week 24, Week 48
Reported as:
Mean · scores on a scale
Phase I and Phase II: Change in EORTC QLQ-C30 Scores From Baseline Compared to Week 24 & Week 48
scores on a scaleLDE225 400mg + INC424 10mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Glob. Health Status/Qol: Wk 25 (n=6,7,5,19)-2.8 ± 21.52-2.4 ± 21.9016.7 ± 27.642.6 ± 22.75
Glob. Health Status/Qol: Wk 49(n=4,4,4,10)-2.1 ± 23.9414.6 ± 45.33-0.0 ± 20.41-3.3 ± 24.91
Phys. Func: Wk 25 (n=6,7,5,19)15.6 ± 25.88-1.0 ± 14.1017.3 ± 16.731.0 ± 23.74
Phys. Func: Wk 49 (n=4,4,4,10)25.0 ± 16.67-10.0 ± 25.8215.0 ± 22.036.0 ± 15.85
Role Func: Wk 25 (n=6,7,5,19)33.3 ± 39.44-7.1 ± 18.9016.7 ± 20.417.9 ± 32.09
Role Func: Wk 49 (n=4,4,4,10)41.7 ± 21.52-33.3 ± 27.2212.5 ± 25.0010.2 ± 22.50
Emo. Func: Wk 25 (n=6,7,5,19)25.0 ± 16.67-8.3 ± 31.185.6 ± 12.422.5 ± 18.61
Emo. Func: Wk 49 (n=4,4,4,10)33.3 ± 11.79-12.5 ± 41.670.0 ± 15.21-2.5 ± 10.43
Cog. Func: Wk 25 (n=6,7,5,1914.6 ± 18.77-6.3 ± 19.80-3.3 ± 13.942.6 ± 18.64
Cog. Func: Wk 49 (n=4,4,4,10)20.8 ± 15.96-8.3 ± 28.874.2 ± 8.33-5.0 ± 22.29
Soc. Func: Wk 25 (n=6,7,4,19)8.3 ± 39.09-7.1 ± 18.9012.5 ± 15.96-2.6 ± 24.38
Soc. Func: Wk 49 (n=3,4,4,10)16.7 ± 16.67-4.2 ± 8.3312.5 ± 25.00-3.3 ± 18.92
Fatigue: Wk 25 (n=6,7,5,19)-20.4 ± 25.74-1.6 ± 26.78-28.9 ± 16.85-8.8 ± 26.86
Fatigue: Wk 49 (n=4,4,4,10)-27.8 ± 6.420. ± 15.71-33.3 ± 18.144.4 ± 36.74
Naus & Vom: Wk 25 (n=6,7,5,19)-5.6 ± 13.61-4.8 ± 18.54-3.3 ± 7.45-3.5 ± 11.89
Naus & Vom: Wk 49 (n=4,4,4,10)-4.2 ± 15.964.2 ± 28.460.0 ± 13.61-10.0 ± 11.65
Pain: Wk 25 (n=6,7,5,18)-11.1 ± 40.37-4.8 ± 38.14-26.7 ± 25.28-8.3 ± 21.58
Pain: Wk 49 (n=4,4,4,10)25.0 ± 21.52-8.3 ± 56.93-20.8 ± 25.003.3 ± 10.54
Dyspnoea: Wk 25 (n=6,7,5,19)-33.3 ± 29.81-4.8 ± 29.99-6.7 ± 14.91-1.8 ± 26.00
Dyspnoea: Wk 49 (n=4,4,4,10)-33.3 ± 27.22-16.7 ± 43.030.0 ± 0.006.7 ± 26.29
Insomnia: Wk 25 (n=6,7,5,19)-22.2 ± 27.220.0 ± 38.49-33.3 ± 23.57-17.5 ± 34.01
Insomnia: Wk 49 (n=4,4,4,10)-25.0 ± 31.918.3 ± 16.67-33.3 ± 27.22-33.3 ± 41.57
Appetite loss: Wk 25 (n=6,7,5,19)-27.8 ± 25.094.8 ± 12.60-13.3 ± 18.26-12.3 ± 29.84
Appetite loss: Wk 49 (n=4,4,4,10)-25.0 ± 41.948.3 ± 16.67-16.7 ± 19.250.0 ± 44.44
Constipation: Wk 25 (n=6,7,5,19)-11.1 ± 17.210.0 ± 0.0013.3 ± 29.817.0 ± 30.59
Constipation: Wk 49 (n=4,4,4,10)-33.3 ± 47.140.0 ± 27.228.3 ± 16.673.3 ± 36.68
Diarrhoea: Wk 25 (n=6,7,5,19)5.6 ± 64.69-9.5 ± 16.27-13.3 ± 18.26-1.8 ± 20.71
Diarrhoea: Wk 49 (n=4,4,4,10)-8.3 ± 16.67-0.0 ± 27.2216.7 ± 57.74-3.3 ± 18.92
Fin. diff: Wk 25 (n=6,7,5,19)16.7 ± 49.9519.0 ± 32.5320.0 ± 50.558.8 ± 24.45
Fin. diff: Wk 49 (n=4,4,4,10)8.3 ± 63.1025.0 ± 31.910.0 ± 27.223.3 ± 18.92
SecondaryPhase Ib and Phase II: LDE225: PK Parameter: Racc

Racc: Accumulation ratio calculated as AUC0-12h on Week 9 Day 1 divided by AUC0-12h on Week 1 Day 1 \[fold\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 9 Day 1
Reported as:
Median · ratio
Phase Ib and Phase II: LDE225: PK Parameter: Racc
ratioLDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
LDE225 (Week 9, Day 1) (n=4,6,3,13)4.60 (2.61 to 7.03)7.40 (4.38 to 19.6)10.9 (6.41 to 17.0)4.75 (1.84 to 20.0)
SecondaryPhase Ib and Phase II: INC424: PK Parameter: T1/2

T1/2: Elimination half-life associated with the terminal slope (lambda_z) of a semi logarithmic concentration-time curve \[time\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1
Reported as:
Median · hour (h)
Phase Ib and Phase II: INC424: PK Parameter: T1/2
hour (h)LDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Phase Ib and Phase II: INC424: PK Parameter: T1/21.81 (1.66 to 3.65)2.42 (1.28 to 3.14)2.20 (1.96 to 2.84)1.99 (1.34 to 3.10)
SecondaryPhase Ib and Phase II: INC424: PK Parameter: Vss/F

Vss/F: Apparent volume of distribution at steady state after oral administration \[volume\]

Time frame:
0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1
Reported as:
Median · Litre (L)
Phase Ib and Phase II: INC424: PK Parameter: Vss/F
Litre (L)LDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)
Phase Ib and Phase II: INC424: PK Parameter: Vss/F63.7 (44.5 to 86.5)67.1 (41.0 to 75.7)53.1 (47.7 to 80.5)54.5 (22.9 to 102)

Adverse events

Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 1505 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225 400 mg + INC424 10 mg1/8 (12.5%)5/8 (62.5%)8/8 (100%)
LDE225 400 mg + INC424 15 mg1/10 (10%)6/10 (60%)10/10 (100%)
LDE225 400 mg + INC424 20 mg1/5 (20%)2/5 (40%)5/5 (100%)
LDE225 400 mg + INC424 20 mg (Dose Expansion)1/27 (3.7%)13/27 (48.1%)27/27 (100%)
All Patients4/50 (8%)26/50 (52%)50/50 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventLDE225 400 mg + INC424 10 mgLDE225 400 mg + INC424 15 mgLDE225 400 mg + INC424 20 mgLDE225 400 mg + INC424 20 mg (Dose Expansion)All Patients
PyrexiaGeneral disorders2/80/100/53/275/50
Gastric ulcerGastrointestinal disorders0/80/101/50/271/50
Gastrointestinal haemorrhageGastrointestinal disorders0/82/100/50/272/50
Blood creatine phosphokinase increasedInvestigations0/82/100/53/275/50
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/101/51/272/50
Atrial fibrillationCardiac disorders1/80/100/50/271/50
Right ventricular failureCardiac disorders1/80/100/50/271/50
Duodenal ulcer haemorrhageGastrointestinal disorders1/80/100/50/271/50
Gastric ulcer haemorrhageGastrointestinal disorders1/80/100/50/271/50
Face oedemaGeneral disorders1/80/100/50/271/50
Most frequent other events
Showing 10 of 170
Most frequent other events
EventLDE225 400 mg + INC424 10 mgLDE225 400 mg + INC424 15 mgLDE225 400 mg + INC424 20 mgLDE225 400 mg + INC424 20 mg (Dose Expansion)All Patients
AnaemiaBlood and lymphatic system disorders5/84/104/516/2729/50
DiarrhoeaGastrointestinal disorders3/83/104/511/2721/50
Muscle spasmsMusculoskeletal and connective tissue disorders3/86/104/518/2731/50
FatigueGeneral disorders6/83/100/58/2717/50
AlopeciaSkin and subcutaneous tissue disorders3/87/103/512/2725/50
ThrombocytopeniaBlood and lymphatic system disorders3/82/103/57/2715/50
Blood creatine phosphokinase increasedInvestigations1/82/103/512/2718/50
DysgeusiaNervous system disorders3/84/103/59/2719/50
PyrexiaGeneral disorders0/82/102/57/2711/50
NasopharyngitisInfections and infestations0/82/102/52/276/50

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15 mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)Total
Mean70.9 ± 5.1959.9 ± 11.5964.6 ± 13.1867.4 ± 10.0266.2 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)LDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15 mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)Total
Female151815
Male7541935
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LDE225 400mg + INC424 10 mg (Dose Escalation Phase)LDE225 400mg + INC424 15 mg (Dose Escalation Phase)LDE225 400mg + INC424 20mg (Dose Escalation Phase)LDED225 400mg + INC424 20mg (Dose Expansion Phase)Total
American Indian or Alaska Native00000
Asian20013
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White61052647
More than one race00000
Unknown or Not Reported00000
08

Study locations

18 sites
  • Novartis Investigative Site
    Camperdown, New South Wales NSW, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Galway, Ireland
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Reggio Calabria, RC 89124, Italy
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3015 GD, Netherlands
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Glasgow, Scotland G12 0YN, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Gupta V, Wolleschak D, Hasselbalch H, Vannucchi AM, Koschmieder S, Cervantes F, Li Y, Dong T, Wroclawska M, Bharathy S, Harrison C. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Adv. 2020 Jul 14;4(13):3063-3071. doi: 10.1182/bloodadvances.2019001212. PubMed 32634234 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Apr 2018, 59 months.

Results were first posted in Apr 2020, 2 years after primary completion.

Of 26 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's 59 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2013
First posted
Feb 8, 2013
StartActual
May 8, 2013
Primary completionActual
Apr 10, 2018
CompletionActual
Apr 10, 2018
Results first posted
Apr 15, 2020
Last update
Apr 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01787552
Responsible party
Sponsor
First posted
Feb 8, 2013
Start date
May 8, 2013
Primary completion
Apr 10, 2018
Completion
Apr 10, 2018
Results posted
Apr 15, 2020
Last update
Apr 15, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion